Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12169977 | PMC |
| http://dx.doi.org/10.21037/tau-2025-13 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Robotic versus laparoscopic total mesorectal excision for mid-low rectal cancer after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis of oncological, perioperative, and survival-related outcomes.
J Robot Surg
September 2025
Department of Oncology, Shengli Oilfield Central Hospital, Dongying, China.
A major cause of cancer death, colorectal cancer is becoming more common in younger people. The comparative effectiveness of robotic versus laparoscopic total mesorectal excision (TME) as surgical interventions for mid-low rectal cancer following neoadjuvant chemoradiotherapy (nCRT) remains uncertain. To systematically evaluate oncological, perioperative, and survival outcomes of robotic versus laparoscopic surgery for mid-low rectal cancer following nCRT.
View Article and Find Full Text PDFThree-year outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma: a real-world retrospective study.
J Gastrointest Surg
September 2025
Department of thoracic surgery, Army Medical Center of PLA, Chongqing, China. Electronic address:
Background: The objective of this study was to evaluate the efficacy, safety, as well as the 3-year survival outcomes of neoadjuvant immunotherapy with chemotherapy (NICT) plus surgery in patients with locally advanced esophageal squamous cell carcinoma (ESCC) in real-world settings.
Methods: We performed a retrospective analysis of patients with locally advanced ESCC who underwent surgery after NICT in our hospital between May 2019 and Mar 2022, with a median follow-up of 37.6 months.
The association of pre-neoadjuvant SUVmax and post-neoadjuvant change in SUVmax on FDG-PET with survival after oesophagectomy for cancer.
J Gastrointest Surg
September 2025
Department of Upper Gastrointestinal and Hepatobiliary Surgery, Royal Prince Alfred Hospital, Sydney, Australia; RPA Institute of Academic Surgery, Sydney, Australia; School of Medicine, University of Sydney, Sydney, Australia; Surgical Outcomes Research Centre (SOuRCe), Sydney, Australia.
Background: 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is currently widely used in staging and re-staging oesophageal cancer after neoadjuvant therapy. The maximal standardized uptake value (SUVmax) is a reproducible parameter that may predict survival. This study aimed to determine the prognostic significance of SUVmax and the change in SUVmax after neoadjuvant treatment (ΔSUVmax) on overall and disease-free survival.
View Article and Find Full Text PDFctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma.
Cell Rep Med
August 2025
Department of Thoracic Surgery, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Institute of Thoracic Oncology, Shanghai 200030, China. Electronic address:
The diagnostic accuracy of circulating tumor DNA (ctDNA) for detecting molecular residual disease (MRD) after multimodal treatment remains unclear. In a prospective cohort of 132 patients with locally advanced esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant chemoradiotherapy (nCRT) followed by clinical response evaluation and surgery, tumor-informed personalized-panel and fixed-panel ctDNA assays are applied to serial blood samples. Personalized ctDNA assay demonstrates a superior baseline detection rate (99.
View Article and Find Full Text PDFImmunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses.
ESMO Open
September 2025
Academic Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties, University of Genova, Genova, Italy.
Background: Immunotherapy has rapidly changed the treatment of early-stage non-small-cell lung cancer (NSCLC) in recent years. We aimed to summarize available evidence on the use of immunotherapy in neoadjuvant/perioperative and adjuvant settings for resectable NSCLC and explore some controversial subgroups.
Materials And Methods: Systematic literature research was carried out for randomized controlled trials of neoadjuvant/perioperative chemo-immunotherapy or adjuvant immunotherapy for resectable NSCLC.